Neurotrophic Keratitis Treatment Global Market Opportunities And Strategies To 2034
상품코드:1729121
리서치사:The Business Research Company
발행일:2025년 05월
페이지 정보:영문 330 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 신경영양성 각막염 치료 시장 규모는 2019년 3억 1,369만 달러에 달했고 2024년까지 27.00% 이상의 CAGR을 나타냈습니다.
당뇨병의 높은 유병률
당뇨병의 높은 유병률은 과거의 기간에 신경영양성 각막염 치료 시장의 성장을 가속했습니다. 각막의 보호반사나 치유능력이 상실되어 궤양이나 감염증에 걸리기 쉬워지므로 신경영양성 각막염을 발병할 가능성이 높아집니다. 예를 들어, 벨기에에 본사를 둔 각국 당뇨병 협회의 산하 조직인 국제당뇨병연맹(IDF)에 따르면 2021년 전 세계 20-79세 성인 5억 3,700만 명이 당뇨병에 걸렸으며, 이 중 4분의 3 이상이 저소득 및 중간 소득 국가에 거주하고 있습니다. 이 질병으로 인해 약 670만 명이 사망했으며, 이는 5초마다 한 명씩 사망하는 것과 같습니다. 당뇨병과 관련된 의료비 지출은 9,660억 달러로 지난 15년 동안 316% 증가했습니다. 또한 5억 4,100만 명의 성인이 내당능 장애(IGT)를 앓고 있어 제2형 당뇨병 발병 위험이 높아졌습니다. 또한 미국 국가 공중 보건 기관인 질병통제예방센터(CDC)가 발표한 전국 당뇨병 통계 보고서에 따르면 2021년 미국 시민의 11.6%, 즉 모든 연령대의 3,840만 명이 당뇨병을 앓은 것으로 나타났습니다.
이 보고서는 세계의 신경영양성 각막염 치료 시장에 대한 조사 분석을 통해 시장 특징, 각 지역 시장 규모 및 예측, 경쟁 구도, 시장 기회 및 전략 등의 정보를 제공합니다.
목차
제1장 주요 요약
신경영양성 각막염 치료 - 시장의 매력과 거시경제 상황
제2장 목차
제3장 표 목록
제4장 그림 목록
제5장 보고서 구성
제6장 시장 특징
일반적인 시장의 정의
요약
신경영양성 각막염 치료 시장 정의와 세분화
시장 세분화 : 치료별
국소 항생제
재조합 인간 신경 성장 인자(rhNGF)
양막 이식
각막 성형술
기타 치료
시장 세분화 : 투여 경로별
구강
국소
기타 투여 경로
시장 세분화 : 최종 사용자별
병원
재택치료
전문 클리닉
기타 최종 사용자
제7장 주요 시장 동향
각막 조직편에 의한 원추 각막 치료의 혁신
수포성 각막증 환자에게 새로운 희망을 가져다주는 혁신적인 세포 요법
캐나다 최초의 프리로드 DMEK 이식이 실현되는 공동 연구
제8장 세계의 신경영양성 각막염 치료 성장 분석, 전략적 분석 프레임워크
신경영양성 각막염 치료의 PESTEL 분석
최종 이용 산업의 분석
병원
재택치료
전문센터
기타 최종 사용자
세계의 신경영양성 각막염 치료 시장 성장률 분석
시장 규모
시장 성장 실적(2019-2024년)
시장 성장 촉진요인(2019-2024년)
시장 성장 억제요인(2019-2024년)
시장 성장 예측(2024-2029년, 2034년)
시장 성장 촉진요인(2024년-2029년)
시장 성장 억제요인(2024년-2029년)
성장요인 예측
양적 성장 요인
성장 촉진요인
성장 억제요인
세계의 신경영양성 각막염 치료 전체 시장(TAM)
제9장 세계의 신경영양성 각막염 치료 시장 세분화
세계의 신경영양성 각막염 치료 시장 : 치료별, 분석과 예측(2019-2024년, 2029년, 2034년)
세계의 신경영양성 각막염 치료 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2029년, 2034년)
세계의 신경영양성 각막염 치료 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2029년, 2034년)
세계의 신경영양성 각막염 치료 시장 : 국소 항생제별 : 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
세계의 신경영양성 각막염 치료 시장 : 재조합 인간 신경 성장 인자(rhNGF)별 : 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
세계의 신경영양성 각막염 치료 시장 : 양막 이식별 : 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
세계의 신경영양성 각막염 치료 시장 : 각막 성형술별 : 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
세계의 신경영양성 각막염 치료 시장 : 기타 치료별 : 유형별, 분석과 예측(2019-2024년, 2029년, 2034년)
제10장 신경영양성 각막염 치료 시장 : 지역과 국가의 분석
세계의 신경영양성 각막염 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2029년, 2034년)
세계의 신경영양성 각막염 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2029년, 2034년)
제11장 아시아태평양 시장
제12장 서유럽 시장
제13장 동유럽 시장
제14장 북미 시장
제15장 남미 시장
제16장 중동 시장
제17장 아프리카 시장
제18장 경쟁 구도와 기업 프로파일
기업 프로파일
Dompe Farmaceutici SpA
BRIM Biotechnology Inc.
Recordati SpA
Oyster Point Pharma Inc.
HLB Therapeutics Co. Ltd.
제19장 기타 주요 기업과 혁신적 기업
Neuroptika Inc.
Aurolab
ReGenTree LLC
Claris Biotherapeutics Inc.
Mime Tech
RegeneRx Biopharmaceuticals
제20장 경쟁 벤치마킹
제21장 경쟁 대시보드
제22장 주요 인수합병(M&A)
Bausch Lomb Acquired Novartis AG
HLB Group Acquired RegeneRx Biopharmaceuticals Inc
제23장 기회와 전략
세계의 신경영양성 각막염 치료 시장 - 가장 새로운 기회를 제공하는 국가(2029년)
세계의 신경영양성 각막염 치료 시장 - 가장 새로운 기회를 제공하는 부문(2029년)
세계의 신경영양성 각막염 치료 시장 - 성장 전략(2029년)
시장 동향에 기초한 전략
경쟁 전략
제24장 신경영양성 각막염 치료 시장 : 결론과 제안
결론
권고
제품
장소
가격
판촉
사람들
제25장 부록
KTH
영문 목차
영문목차
Neurotrophic keratitis treatment refers to the therapies and medical interventions designed to manage and treat neurotrophic keratitis (NK), a rare degenerative disease of the cornea caused by impaired corneal nerve function. This condition leads to decreased or absent corneal sensation, resulting in impaired healing, persistent epithelial defects and corneal ulceration, which can progress to perforation in severe cases. comprises pharmaceutical drugs, surgical interventions and regenerative therapies aimed at restoring corneal integrity, preventing complications and improving patients' vision and quality of life.
The neurotrophic keratitis treatment market consists of sales of neurotrophic keratitis treatments and related services by entities (organizations, sole traders and partnerships) that develop and provide treatments to address the underlying nerve damage, promote corneal healing and prevent disease progression. The use of neurotrophic keratitis treatments depends on the severity of the disease, which is classified into three stages: early-stage epithelial irregularities (Stage I), persistent epithelial defects (Stage II) and corneal ulceration or perforation (Stage III).
The global neurotrophic keratitis treatment market was valued at $313.69 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 27.00%.
High Prevalence Of Diabetes
The high prevalence of diabetes drove the growth of the neurotrophic keratitis treatment market during the historic period. Chronic hyperglycemia in diabetic patients can lead to diabetic neuropathy, which affects the corneal nerves, impairing their ability to detect and respond to injuries. This increases the likelihood of developing neurotrophic keratitis, as the cornea loses its protective reflexes and healing capacity, making it more vulnerable to ulcers and infections. For example, according to the International Diabetes Federation (IDF), a Belgium-based umbrella organization of national diabetes associations, diabetes affected 537 million adults aged 20-79 worldwide in 2021, with over three-quarters residing in low- and middle-income countries. The disease caused approximately 6.7 million deaths, equating to one death every five seconds. Health expenditures related to diabetes reached USD 966 billion, marking a 316% increase over the past 15 years. Further, 541 million adults had impaired glucose tolerance (IGT), heightening their risk of developing type 2 diabetes. Additionally, according to the National Diabetes Statistics Report published by the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, 11.6% of US citizens or 38.4 million people of all ages, suffered from diabetes in 2021. With age, the percentage of people with diabetes rose and among those 65 years of age or older, it reached 29.2%. Therefore, the high prevalence of diabetes contributed to the growth of the neurotrophic keratitis treatment market.
Revolutionizing Keratoconus Treatment With Contoured Corneal Tissue Segments
Major companies operating in the neurotrophic keratitis treatment market are focusing on revolutionizing keratoconus treatment with contoured corneal tissue segments. By developing contoured corneal tissue segments, companies aim to improve the structural integrity of the cornea while also potentially promoting nerve regeneration and better healing. These segments can be precisely designed to match the patient's specific corneal anatomy, offering a personalized treatment approach that enhances both mechanical stability and sensory function. For instance, in June 2024, CorneaGen, a US-based developer of medical devices, launched the Corneal Tissue Addition for Keratoplasty (CTAK), a solution designed for corneal contouring in keratoconic eyes. CTAK provides patient-ready, gamma-irradiated, sterile, non-immunogenic corneal tissue segments, laser-cut and customized to the patient's specific cone severity and location. This advancement aims to improve surgical outcomes and make optimal use of corneal donations.
The global neurotrophic keratitis treatment market is highly concentrated, with large player dominating the market. The top 1 competitor in the market made up 100% of the total market in 2023.
Neurotrophic Keratitis Treatment Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global neurotrophic keratitis treatment market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for neurotrophic keratitis treatment? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The neurotrophic keratitis treatment market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider neurotrophic keratitis treatment market; and compares it with other markets.
The report covers the following chapters
Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by treatment, by route of administration and by end-user.
Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by treatment, by route of administration and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
Regional Market Size and Growth - Regional market size forecast (2030-2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Other Major And Innovative Companies - Details on the company profiles of other major and innovative companies in the market.
Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
Competitive Dashboard - Briefs on competitive dashboard of major players.
Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
Recent Developments - Information on recent developments in the market covered in the report.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for neurotrophic keratitis treatment providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Treatment: Topical Antibiotics; Recombinant Human Nerve Growth Factor (RhNGF); Amniotic Membrane Transplantation; Keratoplasty; Other Treatments
2) By Route Of Administration: Oral; Topical; Other Routes Of Administration
3) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; neurotrophic keratitis treatment indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
8.8 Global Neurotrophic Keratitis Treatment Total Addressable Market (TAM)
9 Global Neurotrophic Keratitis Treatment Market Segmentation
9.1 Global Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.2 Global Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.3 Global Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.4 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation Of Topical Antibiotics, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.5 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Recombinant Human Nerve Growth Factor (rhNGF), By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.6 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Amniotic Membrane Transplantation, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.7 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Keratoplasty, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.8 Global Neurotrophic Keratitis Treatment Market, Sub-Segmentation By Other Treatments, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
10 Neurotrophic Keratitis Treatment Market, Regional and Country Analysis
10.1 Global Neurotrophic Keratitis Treatment Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
10.2 Global Neurotrophic Keratitis Treatment Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11 Asia-Pacific Market
11.1 Summary
11.2 Market Overview
11.2.1 Region Information
11.2.2 Market Information
11.2.3 Background Information
11.2.4 Government Initiatives
11.2.5 Regulations
11.2.6 Regulatory Bodies
11.2.7 Major Associations
11.2.8 Taxes Levied
11.2.9 Corporate Tax Structure
11.2.10 Investments
11.2.11 Major Companies
11.3 Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.4 Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.5 Asia-Pacific Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.6 Asia-Pacific Neurotrophic Keratitis Treatment Market: Country Analysis
11.7 China Market
11.8 Summary
11.9 Market Overview
11.9.1 Country Information
11.9.2 Market Information
11.9.3 Background Information
11.9.4 Government Initiatives
11.9.5 Regulations
11.9.6 Regulatory Bodies
11.9.7 Major Associations
11.9.8 Taxes Levied
11.9.9 Corporate Tax Structure
11.9.10 Major Companies
11.10 China Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.11 China Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.12 China Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.13 India Market
11.14 India Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.15 India Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.16 India Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.17 Japan Market
11.18 Market Overview
11.18.1 Country Information
11.18.2 Market Information
11.18.3 Background Information
11.18.4 Government Initiatives
11.18.5 Regulations
11.18.6 Regulatory Bodies
11.18.7 Major Associations
11.18.8 Taxes Levied
11.18.9 Corporate Tax Structure
11.18.10 Investments
11.18.11 Major Companies
11.19 Japan Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.20 Japan Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.21 Japan Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.22 Australia Market
11.23 Australia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.24 Australia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.25 Australia Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.26 Indonesia Market
11.27 Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.28 Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.29 Indonesia Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.30 South Korea Market
11.31 Market Overview
11.31.1 Country Information
11.31.2 Market Information
11.31.3 Background Information
11.31.4 Government Initiatives
11.31.5 Regulations
11.31.6 Regulatory Bodies
11.31.7 Major Associations
11.31.8 Taxes Levied
11.31.9 Corporate Tax Structure
11.31.10 Investment
11.31.11 Major Companies
11.32 South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.33 South Korea Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.34 South Korea Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12 Western Europe Market
12.1 Summary
12.2 Market Overview
12.2.1 Region Information
12.2.2 Market Information
12.2.3 Background Information
12.2.4 Government Initiatives
12.2.5 Regulations
12.2.6 Regulatory Bodies
12.2.7 Major Associations
12.2.8 Taxes Levied
12.2.9 Corporate tax structure
12.2.10 Investments
12.2.11 Major Companies
12.3 Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.4 Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.5 Western Europe Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.6 Western Europe Neurotrophic Keratitis Treatment Market: Country Analysis
12.7 UK Market
12.8 UK Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.9 UK Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.10 UK Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.11 Germany Market
12.12 Germany Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.13 Germany Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.14 Germany Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.15 France Market
12.16 France Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.17 France Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.18 France Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.19 Italy Market
12.20 Italy Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.21 Italy Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.22 Italy Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.23 Spain Market
12.24 Spain Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.25 Spain Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.26 Spain Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13 Eastern Europe Market
13.1 Summary
13.2 Market Overview
13.2.1 Region Information
13.2.2 Market Information
13.2.3 Background Information
13.2.4 Government Initiatives
13.2.5 Regulations
13.2.6 Regulatory Bodies
13.2.7 Major Associations
13.2.8 Taxes Levied
13.2.9 Corporate Tax Structure
13.2.10 Major companies
13.3 Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.4 Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.5 Eastern Europe Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.6 Eastern Europe Neurotrophic Keratitis Treatment Market: Country Analysis
13.7 Russia Market
13.8 Russia Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.9 Russia Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.10 Russia Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14 North America Market
14.1 Summary
14.2 Market Overview
14.2.1 Region Information
14.2.2 Market Information
14.2.3 Background Information
14.2.4 Government Initiatives
14.2.5 Regulations
14.2.6 Regulatory Bodies
14.2.7 Major Associations
14.2.8 Taxes Levied
14.2.9 Corporate Tax Structure
14.2.10 Investments
14.2.11 Major Companies
14.3 North America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.4 North America Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.5 North America Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.6 North America Neurotrophic Keratitis Treatment Market: Country Analysis
14.7 USA Market
14.8 Summary
14.9 Market Overview
14.9.1 Country Information
14.9.2 Market Information
14.9.3 Background Information
14.9.4 Government Initiatives
14.9.5 Regulations
14.9.6 Regulatory Bodies
14.9.7 Major Associations
14.9.8 Taxes Levied
14.9.9 Corporate Tax Structure
14.9.10 Investments
14.9.11 Major Companies
14.10 USA Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.11 USA Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.12 USA Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.13 Canada Market
14.14 Summary
14.15 Market Overview
14.15.1 Country Information
14.15.2 Market Information
14.15.3 Background Information
14.15.4 Government Initiatives
14.15.5 Regulations
14.15.6 Regulatory Bodies
14.15.7 Major Associations
14.15.8 Taxes Levied
14.15.9 Corporate Tax Structure
14.15.10 Investments
14.15.11 Major Companies
14.16 Canada Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.17 Canada Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.18 Canada Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15 South America Market
15.1 Summary
15.1 Market Overview
15.1.1 Region Information
15.1.2 Market Information
15.1.3 Background Information
15.1.4 Government Initiatives
15.1.5 Regulations
15.1.6 Regulatory Bodies
15.1.7 Major Associations
15.1.8 Taxes Levied
15.1.9 Corporate Tax Structure
15.1.10 Major Companies
15.2 South America Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.3 South America Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.4 South America Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.5 South America Neurotrophic Keratitis Treatment Market: Country Analysis
15.6 Brazil Market
15.7 Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.8 Brazil Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.9 Brazil Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16 Middle East Market
16.1 Summary
16.2 Market Overview
16.2.1 Region Information
16.2.2 Market Information
16.2.3 Background Information
16.2.4 Government Initiatives
16.2.5 Regulations
16.2.6 Regulatory Bodies
16.2.7 Major Associations
16.2.8 Taxes Levied
16.2.9 Corporate Tax Structure
16.2.10 Major Companies
16.3 Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.4 Middle East Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.5 Middle East Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17 Africa Market
17.1 Summary
17.2 Market Overview
17.2.1 Region Information
17.2.2 Market Information
17.2.3 Background Information
17.2.4 Government Initiatives
17.2.5 Regulations
17.2.6 Regulatory Bodies
17.2.7 Major Associations
17.2.8 Taxes Levied
17.2.9 Corporate Tax Structure
17.2.10 Major Companies
17.3 Africa Neurotrophic Keratitis Treatment Market, Segmentation By Treatment, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.4 Africa Neurotrophic Keratitis Treatment Market, Segmentation By Route of Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.5 Africa Neurotrophic Keratitis Treatment Market, Segmentation By End User, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
18 Competitive Landscape And Company Profiles
18.1 Company Profiles
18.2 Dompe Farmaceutici S.p.A.
18.2.1 Company Overview
18.2.2 Products And Services
18.2.3 Business Strategy
18.2.4 Financial Overview
18.3 BRIM Biotechnology Inc.
18.3.1 Company Overview
18.3.2 Products And Services
18.3.3 Business Strategy
18.3.4 Financial Overview
18.4 Recordati S.p.A.
18.4.1 Company Overview
18.4.2 Products And Services
18.4.3 Financial Overview
18.5 Oyster Point Pharma Inc.
18.5.1 Company Overview
18.5.2 Products And Services
18.5.3 Business Strategy
18.5.4 Financial Overview
18.6 HLB Therapeutics Co. Ltd.
18.6.1 Company Overview
18.6.2 Products And Services
18.6.3 Financial Overview
19 Other Major And Innovative Companies
19.1 Neuroptika Inc.
19.1.1 Company Overview
19.1.2 Product And Services
19.2 Aurolab
19.2.1 Company Overview
19.2.2 Product And Services
19.3 ReGenTree LLC
19.3.1 Company Overview
19.3.2 Product And Services
19.4 Claris Biotherapeutics Inc.
19.4.1 Company Overview
19.4.2 Product And Services
19.5 Mime Tech
19.5.1 Company Overview
19.5.2 Product And Services
19.6 RegeneRx Biopharmaceuticals
19.6.1 Company Overview
19.6.2 Product And Services
20 Competitive Benchmarking
21 Competitive Dashboard
22 Key Mergers And Acquisitions
22.1 Bausch + Lomb Acquired Novartis AG
22.2 HLB Group Acquired RegeneRx Biopharmaceuticals Inc
23 Opportunities And Strategies
23.1 Global Neurotrophic Keratitis Treatment Market In 2029 - Countries Offering Most New Opportunities
23.2 Global Neurotrophic Keratitis Treatment Market In 2029 - Segments Offering Most New Opportunities
23.3 Global Neurotrophic Keratitis Treatment Market In 2029 - Growth Strategies
23.3.1 Market Trend Based Strategies
23.3.2 Competitor Strategies
24 Neurotrophic Keratitis Treatment Market, Conclusions And Recommendations
